Effects of nebulized budesonide as an adjunct to standard treatment of asthma
exacerbations: a randomized, double-blind, placebo-controlled trial.
Author(s): Akhtaruzzaman M(1), Ahmed SU, Hoque MA, Choudhury AM, Hossain MA, Islam MN, Begum
B, Dhar SK, Maniruzzaman M, Rashid FB, Kabir A, Hasan MM, Chowdhury B, Khan AH.
Affiliation(s): Author information:
(1)Dr Muhammad Akhtaruzzaman, Medical Officer Department of Paediatrics,
Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh.
Publication date & source: 2014, Mymensingh Med J. , 23(3):418-25
This study was done to determine the effects and outcome of inhaled budesonide in
addition to standard management of asthma exacerbations in pediatric age groups.
A randomized, double-blind, placebo controlled trial was done in a tertiary care
urban hospital. Sixty six children aged 5 to 15 years with moderate to severe
asthma exacerbations were eligible. All patients received a single dose of
prednisolone 1mg/kg orally as first dose of systemic corticosteroids and then
salbutamol (0.15mg/kg) and ipratropium bromide (500mcg) was nebulized every 20
minutes for 3 doses and then hourly for 2 hours as a part of standard treatment
of asthma exacerbations. The intervention was 2mg (4mL) of budesonide or 4mL of
normal saline which was nebulized immediately after the 1st dose of nebulized
salbutamol and ipratropium bromide. The baseline characteristics of the
budesonide group (n=33) and placebo group (n=33) were similar, but at 1 hour, 2
hour and 3 hour PEFR, respiratory rate, pulse rate, SaO2 and asthma score were
significantly improved in the budesonide group compared to placebo group
(p<0.01). The positive immediate effect of nebulized budesonide added to standard
treatment of asthma exacerbations is an encouraging finding for further
investigations of its routine use in the treatment of asthma exacerbations in
children.
|